| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V122177 | (S)-IP-DK143 | (S)-IP-DK143 is a polymer micelle formulation. | |
|
V3801 | AZD-0364 | 2097416-76-5 | AZD0364 is a potent and selective oral inhibitor of ERK1/2 that is efficacious in both monotherapy and combination therapy in models of NSCLC. |
|
V4176 | BAY885 | 2307249-33-6 | BAY-885 is a novel, highly potent and selective ERK5/MAPK7 inhibitor with IC50 of 40 nM. |
|
V130132 | BI-113823 | 1119282-90-4 | BI-113823 is an orally effective bradykinin B1 receptor antagonist that crosses the blood-brain barrier, with a Ki value of 5.3 nM for human receptors and 13.3 nM for rat receptors. |
|
V0469 | DEL-22379 | 181223-80-3 | DEL-22379 is a novel, potent,selective, and water-soluble ERK (extracellular signal-related kinase 2) dimerization inhibitor with potential antitumor activity. |
|
V69832 | ERK-IN-7 | 2494010-63-6 | RK-IN-7 (Example 10) is an analog of SHR2415 and a potent ERK inhibitor (antagonist) with IC50s of 5 nM and 7 nM for ERK1 and ERK2, respectively. |
|
V0465 | FR 180204 | 865362-74-9 | FR-180204 (FR180204) is a novel, potent, selectiveand ATP-competitive inhibitor of ERK (extracellular signal-regulated kinase) with potential anti-inflammatory activity and has the potential to be used as a new therapy for rheumatoid arthritis. |
|
V0466 | Ravoxertinib (GDC-0994; RG-7842) | 1453848-26-4 | Ravoxertinib (formerly known as GDC0994; RG7842) is a novel, potent, orally bioavailable inhibitor of extracellular signal-regulated kinase (ERK1/2) with potential antineoplastic activity. |
|
V136853 | GP369 | GP369 is a humanized FGFR2-IIIb specific antibody. | |
|
V137203 | HDAC6-IN-61 | HDAC6-IN-61 is an HDAC6 inhibitor (IC50: 73 nM) that is selective for other HDAC isotypes. | |
|
V137206 | HDAC6-IN-74 | HDAC6-IN-74 is an orally effective selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 value of 0.036 μM. | |
|
V137653 | HYD-1 | 351327-13-4 | HYD-1 is a D-amino acid tumor cell adhesion peptide. |
|
V4122 | MK-8353 | 1184173-73-6 | MK-8353 (also known as SCH900353; SCH-900353) is a novel, potent, selective and orally bioavailable ERK inhibitor with anticancer activity. |
|
V87066 | Napyradiomycin B4 | Napyradiomycin B4 is a napyradiomycin derivative that inhibits RANKL-induced MEK-ERK signaling pathway. | |
|
V142148 | PAK1-IN-2 | PAK1-IN-2 is a selective PAK1 inhibitor with a Ki value of 7.3 nM. | |
|
V142231 | PARP1/ERK IN-1 | PARP1/ERK IN-1 is a dual PARP1/ERK inhibitor with an IC50 of 0.9 nM for PARP1 and 1.8 nM for ERK2. | |
|
V142459 | Peptide E5 | 1643580-44-2 | Peptide E5 is an antagonist that targets the CXCR4/CXCL12 axis. |
|
V142464 | Peptide R analogue 10 | 1998129-59-1 | Peptide R analogue 10 is an analogue of the CXCR4 antagonistic peptide Peptide R, with stronger antagonistic potency, specificity and plasma stability. |
|
V142475 | Perfluoroundecanoic acid-13C7 | Perfluoroundecanoic acid-13C7 is a 13C-labeled perfluoroundecanoic acid. | |
|
V143140 | Prexigebersen sodium scrambled negative control | The Prexigebersen sodium scrambled negative control is a negative control with the sequence of Prexigebersen sodium scrambled. |